Baxter International Stock Price, News & Analysis (NYSE:BAX)

$69.20 1.00 (1.47 %)
(As of 01/19/2018 02:10 PM ET)
Previous Close$68.20
Today's Range$68.32 - $69.47
52-Week Range$45.47 - $69.65
Volume4.38 million shs
Average Volume3.32 million shs
Market Capitalization$38.07 billion
P/E Ratio37.41
Dividend Yield0.95%
Beta0.69

About Baxter International (NYSE:BAX)

Baxter International logoBaxter International Inc., through its subsidiaries, provides renal and hospital products. The Company operates through two segments: Hospital Products and Renal. Its Hospital Products business manufactures sterile intravenous (IV) solutions and administration sets, premixed drugs and drug-reconstitution systems, pre-filled vials and syringes for injectable drugs, IV nutrition products, parenteral nutrition therapies, infusion pumps, inhalation anesthetics and biosurgery products. The Renal business offers a portfolio to meet the needs of patients with end-stage renal disease, or irreversible kidney disease and acute kidney injuries, including technologies and therapies for peritoneal dialysis (PD), hemodialysis (HD), continuous renal replacement therapy (CRRT) and additional dialysis services. Its products are used by hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors' offices and by patients at home under physician supervision.

Receive BAX News and Ratings via Email

Sign-up to receive the latest news and ratings for BAX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Medical Equipment, Supplies & Distribution
Sub-IndustryHealth Care Equipment
SectorHealthcare
SymbolNYSE:BAX
CUSIP07181310
Phone+1-847-9482000

Debt

Debt-to-Equity Ratio0.37%
Current Ratio2.80%
Quick Ratio2.22%

Price-To-Earnings

Trailing P/E Ratio37.4054054054054
Forward P/E Ratio28.48
P/E Growth2.05

Sales & Book Value

Annual Sales$10.16 billion
Price / Sales3.71
Cash Flow$3.50 per share
Price / Cash19.75
Book Value$15.22 per share
Price / Book4.55

Profitability

Trailing EPS$1.85
Net Income$4.97 billion
Net Margins9.88%
Return on Equity15.00%
Return on Assets8.12%

Miscellaneous

Employees48,000
Outstanding Shares544,830,000

Baxter International (NYSE:BAX) Frequently Asked Questions

What is Baxter International's stock symbol?

Baxter International trades on the New York Stock Exchange (NYSE) under the ticker symbol "BAX."

How often does Baxter International pay dividends? What is the dividend yield for Baxter International?

Baxter International announced a quarterly dividend on Tuesday, November 14th. Shareholders of record on Friday, December 1st will be paid a dividend of $0.16 per share on Tuesday, January 2nd. This represents a $0.64 annualized dividend and a yield of 0.92%. The ex-dividend date is Thursday, November 30th. View Baxter International's Dividend History.

How were Baxter International's earnings last quarter?

Baxter International Inc (NYSE:BAX) posted its quarterly earnings data on Wednesday, October, 25th. The medical instruments supplier reported $0.64 earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of $0.59 by $0.05. The medical instruments supplier earned $2.71 billion during the quarter, compared to analyst estimates of $2.66 billion. Baxter International had a return on equity of 15.00% and a net margin of 9.88%. The business's revenue was up 5.8% on a year-over-year basis. During the same period in the previous year, the business posted $0.56 EPS. View Baxter International's Earnings History.

When will Baxter International make its next earnings announcement?

Baxter International is scheduled to release their next quarterly earnings announcement on Thursday, February, 1st 2018. View Earnings Estimates for Baxter International.

What guidance has Baxter International issued on next quarter's earnings?

Baxter International issued an update on its fourth quarter earnings guidance on Wednesday, October, 25th. The company provided EPS guidance of $0.56-0.59 for the period, compared to the Thomson Reuters consensus estimate of $0.60.

Where is Baxter International's stock going? Where will Baxter International's stock price be in 2018?

14 equities research analysts have issued 12-month target prices for Baxter International's stock. Their forecasts range from $62.00 to $75.00. On average, they expect Baxter International's share price to reach $68.92 in the next twelve months. View Analyst Ratings for Baxter International.

What are Wall Street analysts saying about Baxter International stock?

Here are some recent quotes from research analysts about Baxter International stock:

  • 1. According to Zacks Investment Research, "Over the past year, Baxter has outperformed the broader industry in terms of price performance. The company's impressive performance at the hospital products and renal segments hold promise. Baxter launched the oXIRIS set for continuous renal replacement therapy (CRRT) and sepsis management protocols in select markets of Europe, Middle East and Africa recently. Further, the recent launch of DeviceVue, a comprehensive asset tracking solution available exclusively to hospitals, boosts the company’s product portfolio. On the flipside, foreign currency headwinds, intensifying competition and lackluster sales growth have been dampening Baxter’s performance since long. Generic competition for cyclophosphamide is an added headwind. Furthermore, the recent hurricanes are expected to dent the company’s results in the near term. Baxter stock looks a tad expensive at the moment." (1/4/2018)
  • 2. UBS Group AG analysts commented, "Management delivered a solid 7c beat to our EPS estimate (+5c to consensus) driven by Fluid Systems (+$32 mil) and roughly in-line revenues across other major business lines. On the earnings line, higher sales net of COGS (+2c), lower SG&A spend (+8c) and higher non-op income (+2c) were partially offset by higher R&D (-2c) and a higher tax rate (-3c) to deliver a 7c beat to our EPS estimate. We continue to view the Claris deal as a positive, and expect continued solid operating performance, backed up with patient and prudent strategic investment. We remain Neutral on BAX." (2/2/2017)
  • 3. Evercore ISI analysts commented, "BAX reported a solid finish to the year, beating consensus EPS estimates by double digits and initiating above ST EPS guidance. There were several highlights in the 4Q print, both on the topline and operating metrics that made us incrementally more positive on our 'turnaround + long term EPS power underappreciated by Street' thesis. From a revenue perspective, Renal came in above, and management highlighted continued strong adoption of AMIA PD with patient volumes doubling past few Qs (AMIA will be a key long term driver, and these trends bode well). While management guided to 3-4% growth for Renal in FY17, we think the low end of the guidance seems conservative given strength in underlying business + AMIA uptake. Within Fluid Systems, yet another strong high single digit showing highlighted the strength of Sigma Spectrum pump uptake. We found it interesting that guidance assumes 'flattening of Sigma pump in 2017', which we think is a conservative assumption (competitor BDX still expects pump share gains in FY17). Overall, the constant currency growth of ~2% seems conservative, with potential upside in the event of lack of competitive entrants for cyclo business. On the margin front, while FY17 OM of ~15% seems optically below the ~15.7% seen in 2H'16 levels (but equates to an expansion of ~150 bps over FY16), we note that it contemplates about 150 bps of headwinds related to cyclo competition, Fx & TSA rolling off. As such, the ~15% OM guidance seems prudent to us, with possible upside tied to lack of competitive cyclo entrants. Finally, the EPS guide of $2.10-2.18 does not assume any share repo and no contribution from Claris. In light of the impressive free cash increase (FY16 FCF came in 80% above original guidance; FY17 guide of >$1 Bn) and ~$1 Bn of repatriation, we see upside potential to EPS upside tied to capital deployment. All in, this was a solid print, and current levels provide a good entry point for long term holders (we note BAX repurchased $250 MM worth of shares at an avg. of $47.50 in 4Q, which is around current trading levels)." (2/1/2017)

Who are some of Baxter International's key competitors?

Who are Baxter International's key executives?

Baxter International's management team includes the folowing people:

  • Jose E. Almeida, Chairman of the Board, President, Chief Executive Officer (Age 55)
  • James K. Saccaro, Corporate Vice President and Chief Financial Officer (Age 44)
  • Giuseppe Accogli, Senior Vice President, President - Global Businesses (Age 46)
  • Brik V. Eyre, Senior Vice President, President - Americas (Age 53)
  • Marcus Schabacker M.D. Ph.D., Chief Scientific Officer, Corporate Vice President (Age 53)
  • Scott Pleau, Corporate Vice President - Operations (Age 51)
  • Sean Martin, Corporate Vice President, General Counsel
  • Jeanne K. Mason Ph.D., Corporate Vice President - Human Resources (Age 61)
  • Paul Vibert, Corporate Vice President, President - International (Age 57)
  • Thomas T. Stallkamp, Lead Independent Director (Age 70)

Who owns Baxter International stock?

Baxter International's stock is owned by a number of of institutional and retail investors. Top institutional investors include Schwab Charles Investment Management Inc. (0.49%), Bank of Montreal Can (0.29%), Acadian Asset Management LLC (0.12%), Marathon Asset Management LLP (0.10%), National Pension Service (0.09%) and Gateway Investment Advisers LLC (0.08%). Company insiders that own Baxter International stock include Albert P L Stroucken, Brik V Eyre, Carole J Shapazian, Giuseppe Accogli, James R Gavin III, Jeanne K Mason, John D Forsyth, Jose E Almeida, Kornelis J Storm, Peter S Hellman, Third Point Llc and Thomas T Stallkamp. View Institutional Ownership Trends for Baxter International.

Who sold Baxter International stock? Who is selling Baxter International stock?

Baxter International's stock was sold by a variety of institutional investors in the last quarter, including Bank of Montreal Can, Marathon Asset Management LLP, Private Trust Co. NA, Westpac Banking Corp, Oakbrook Investments LLC, First Citizens Bank & Trust Co., Exxonmobil Investment Management Inc. TX and Jaffetilchin Investment Partners LLC. Company insiders that have sold Baxter International company stock in the last year include Albert P L Stroucken, Brik V Eyre, Carole J Shapazian, Giuseppe Accogli, James R Gavin III, Jeanne K Mason, John D Forsyth, Peter S Hellman, Third Point Llc and Thomas T Stallkamp. View Insider Buying and Selling for Baxter International.

Who bought Baxter International stock? Who is buying Baxter International stock?

Baxter International's stock was acquired by a variety of institutional investors in the last quarter, including Acadian Asset Management LLC, Stillwater Investment Management LLC, Schwab Charles Investment Management Inc., State of Alaska Department of Revenue, Gateway Investment Advisers LLC, National Pension Service, Fox Run Management L.L.C. and Sawyer & Company Inc. View Insider Buying and Selling for Baxter International.

How do I buy Baxter International stock?

Shares of Baxter International can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Baxter International's stock price today?

One share of Baxter International stock can currently be purchased for approximately $69.20.

How big of a company is Baxter International?

Baxter International has a market capitalization of $38.07 billion and generates $10.16 billion in revenue each year. The medical instruments supplier earns $4.97 billion in net income (profit) each year or $1.85 on an earnings per share basis. Baxter International employs 48,000 workers across the globe.

How can I contact Baxter International?

Baxter International's mailing address is 1 Baxter Pkwy, DEERFIELD, IL 60015-4625, United States. The medical instruments supplier can be reached via phone at +1-847-9482000 or via email at [email protected]


MarketBeat Community Rating for Baxter International (BAX)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  469 (Vote Outperform)
Underperform Votes:  404 (Vote Underperform)
Total Votes:  873
MarketBeat's community ratings are surveys of what our community members think about Baxter International and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Baxter International (NYSE:BAX) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.712.582.552.54
Ratings Breakdown: 0 Sell Rating(s)
5 Hold Rating(s)
8 Buy Rating(s)
1 Strong Buy Rating(s)
0 Sell Rating(s)
6 Hold Rating(s)
5 Buy Rating(s)
1 Strong Buy Rating(s)
1 Sell Rating(s)
4 Hold Rating(s)
5 Buy Rating(s)
1 Strong Buy Rating(s)
1 Sell Rating(s)
5 Hold Rating(s)
6 Buy Rating(s)
1 Strong Buy Rating(s)
Consensus Price Target: $68.92$67.55$65.73$62.18
Price Target Upside: 2.60% upside5.47% upside4.63% upside2.69% upside

Baxter International (NYSE:BAX) Consensus Price Target History

Price Target History for Baxter International (NYSE:BAX)

Baxter International (NYSE:BAX) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/3/2018Raymond James FinancialUpgradeMarket Perform -> Outperform$73.00MediumView Rating Details
1/3/2018Evercore ISIInitiated CoverageOutperform -> Outperform$71.00MediumView Rating Details
1/2/2018Bank of AmericaUpgradeNeutral -> BuyHighView Rating Details
1/2/2018JPMorgan Chase & Co.UpgradeNeutral -> OverweightHighView Rating Details
11/22/2017Royal Bank of CanadaReiterated RatingHold$66.00N/AView Rating Details
10/26/2017Stifel NicolausReiterated RatingHold$65.00N/AView Rating Details
10/26/2017BarclaysBoost Price TargetOverweight$70.00 -> $73.00N/AView Rating Details
10/26/2017Morgan StanleyBoost Price TargetEqual Weight$59.00 -> $62.00N/AView Rating Details
10/15/2017CowenSet Price TargetHold$68.00N/AView Rating Details
10/13/2017BMO Capital MarketsReiterated RatingBuy$70.00N/AView Rating Details
8/17/2017CitigroupInitiated CoverageNeutral -> Neutral$63.00LowView Rating Details
7/27/2017Leerink SwannReiterated RatingOutperform$67.00 -> $75.00LowView Rating Details
7/26/2017Cantor FitzgeraldSet Price TargetBuy$70.00MediumView Rating Details
5/16/2017Goldman Sachs GroupReiterated RatingConviction-Buy$71.00HighView Rating Details
10/13/2016Wells Fargo & CoInitiated CoverageOutperformN/AView Rating Details
8/15/2016ArgusReiterated RatingHoldN/AView Rating Details
6/13/2016Piper Jaffray CompaniesReiterated RatingOverweight$60.00N/AView Rating Details
5/10/2016Credit Suisse GroupReiterated RatingHoldN/AView Rating Details
(Data available from 1/19/2016 forward)

Earnings

Baxter International (NYSE:BAX) Earnings History and Estimates Chart

Earnings by Quarter for Baxter International (NYSE:BAX)

Baxter International (NYSE BAX) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/1/2018$0.59N/AView Earnings Details
10/25/2017Q3 2017$0.59$0.64$2.66 billion$2.71 billionViewN/AView Earnings Details
7/26/2017Q2 2017$0.57$0.63$2.59 billion$2.61 billionViewN/AView Earnings Details
4/26/2017Q1 2017$0.51$0.58$2.43 billion$2.48 billionViewN/AView Earnings Details
2/1/2017Q416$0.52$0.57$2.65 billion$2.65 billionViewListenView Earnings Details
10/25/2016Q316$0.45$0.56$2.67 billion$2.56 billionViewListenView Earnings Details
7/26/2016Q216$0.40$0.46$2.51 billion$2.60 billionViewListenView Earnings Details
4/26/2016Q116$0.29$0.36$2.35 billion$2.40 billionViewListenView Earnings Details
2/2/2016Q415$0.32$0.43$2.55 billion$2.60 billionViewListenView Earnings Details
10/27/2015Q315$0.29$0.41$2.46 billion$2.49 billionViewListenView Earnings Details
7/29/2015Q215$0.94$1.00$2.40 billion$3.90 billionViewListenView Earnings Details
4/23/2015Q115$0.88$1.00$3.70 billion$3.76 billionViewListenView Earnings Details
1/29/2015Q414$1.31$1.34$4.37 billion$4.47 billionViewListenView Earnings Details
10/16/2014Q314$1.31$1.31$4.21 billion$4.20 billionViewListenView Earnings Details
7/17/2014Q214$1.21$1.26$4.12 billion$4.30 billionViewListenView Earnings Details
4/17/2014Q114$1.10$1.19$3.88 billion$3.95 billionViewListenView Earnings Details
1/23/2014Q413$1.25$1.26$4.25 billion$4.40 billionViewListenView Earnings Details
10/17/2013Q313$1.19$1.19$3.82 billion$3.80 billionViewListenView Earnings Details
7/18/2013Q2 2013$1.13$1.16$3.70 billion$3.67 billionViewListenView Earnings Details
4/18/2013Q1 2013$1.04$1.05$3.49 billion$3.45 billionViewListenView Earnings Details
1/24/2013Q4 2012$1.26$1.26$3.72 billion$3.75 billionViewListenView Earnings Details
10/18/2012$1.14$1.14ViewN/AView Earnings Details
7/19/2012$1.11$1.12ViewN/AView Earnings Details
4/19/2012$1.00$1.01ViewN/AView Earnings Details
1/26/2012$1.17$1.17ViewN/AView Earnings Details
10/20/2011$1.08$1.09ViewN/AView Earnings Details
7/21/2011$1.02$1.07ViewN/AView Earnings Details
4/21/2011$0.93$0.98ViewN/AView Earnings Details
1/27/2011$1.10$1.11ViewN/AView Earnings Details
10/21/2010Q3 2010$0.97$1.01ViewN/AView Earnings Details
7/22/2010Q2 2010$0.92$0.93ViewN/AView Earnings Details
4/22/2010Q1 2010$0.93$0.93ViewN/AView Earnings Details
1/28/2010Q4 2009$1.03$1.03ViewN/AView Earnings Details
10/15/2009Q3 2009$0.96$0.98ViewN/AView Earnings Details
7/16/2009Q2 2009$0.94$0.96ViewN/AView Earnings Details
4/16/2009Q1 2009$0.81$0.83ViewN/AView Earnings Details
1/22/2009Q4 2008$0.89$0.91ViewN/AView Earnings Details
10/16/2008Q3 2008$0.82$0.88ViewN/AView Earnings Details
7/17/2008Q2 2008$0.81$0.85ViewN/AView Earnings Details
4/17/2008Q1 2008$0.72$0.74ViewN/AView Earnings Details
1/24/2008Q4 2007$0.74$0.76ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Baxter International (NYSE:BAX) Earnings Estimates

2018 EPS Consensus Estimate: $2.64
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20182$0.61$0.62$0.62
Q2 20182$0.66$0.67$0.67
Q3 20182$0.67$0.69$0.68
Q4 20182$0.67$0.69$0.68
(Earnings estimates data provided by Zacks Investment Research)

Dividends

Baxter International (NYSE:BAX) Dividend Information

Most Recent Dividend:1/2/2018
Annual Dividend:$0.64
Dividend Yield:0.92%
Dividend Growth:-34.00% (3 Year Average)
Payout Ratio:34.59% (Trailing 12 Months of Earnings)
26.34% (Based on This Year's Estimates)
23.70% (Based on Next Year's Estimates)
Frequency:Quarterly Dividend
Dividend Payments by Quarter for Baxter International (NYSE:BAX)

Baxter International (NYSE:BAX) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
11/14/2017quarterly$0.160.99%11/30/201712/1/20171/2/2018
7/18/2017quarterly$0.161.03%8/30/20179/1/201710/2/2017
5/2/2017quarterly$0.161.14%5/31/20176/2/20177/3/2017
2/21/2017quarterly$0.131.04%3/1/20173/3/20174/3/2017
11/8/2016quarterly$0.131.12%11/30/201612/2/20161/3/2017
7/19/2016quarterly$0.131.11%8/31/20169/2/201610/3/2016
5/3/2016quarterly$0.131.15%6/1/20166/3/20167/1/2016
2/16/2016quarterly$0.121.23%3/2/20163/4/20164/1/2016
11/11/2015quarterly$0.121.21%12/2/201512/4/20151/4/2016
7/29/2015quarterly$0.121.15%9/2/20159/4/201510/1/2015
5/5/2015quarterly$0.523.02%5/28/20156/1/20157/1/2015
2/17/2015quarterly$0.523.04%3/9/20153/11/20154/1/2015
11/11/2014quarterly$0.522.92%12/3/201412/5/20141/2/2015
7/22/2014quarterly$0.522.71%9/3/20149/5/201410/1/2014
5/5/2014quarterly$0.522.81%6/4/20146/6/20147/1/2014
2/18/2014quarterly$0.492.84%3/5/20143/7/20144/1/2014
11/12/2013quarterly$0.492.95%12/4/201312/6/20131/3/2014
7/23/2013quarterly$0.492.66%9/4/20139/6/201310/1/2013
5/6/2013quarterly$0.492.86%6/5/20136/7/20137/1/2013
2/19/2013quarterly$0.452.67%3/6/20133/8/20134/1/2013
(Data available from 1/1/2013 forward)

Insider Trades

Baxter International (NYSE BAX) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 0.05%
Institutional Ownership Percentage: 83.82%
Insider Trades by Quarter for Baxter International (NYSE:BAX)
Institutional Ownership by Quarter for Baxter International (NYSE:BAX)

Baxter International (NYSE BAX) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/2/2018Giuseppe AccogliSVPSell28,641$67.00$1,918,947.00View SEC Filing  
12/4/2017Jeanne K MasonSVPSell33,350$65.25$2,176,087.50124,609View SEC Filing  
11/6/2017Third Point LlcDirectorSell5,000,000$64.23$321,150,000.00View SEC Filing  
9/5/2017Thomas T StallkampDirectorSell8,920$62.28$555,537.6016,263View SEC Filing  
8/25/2017John D ForsythDirectorSell9,440$61.76$583,014.4032,444View SEC Filing  
8/24/2017Carole J ShapazianDirectorSell4,020$61.61$247,672.2013,868View SEC Filing  
8/17/2017Giuseppe AccogliSVPSell12,670$60.96$772,363.2033,286View SEC Filing  
5/23/2017Carole J ShapazianDirectorSell2,618$57.92$151,634.569,848View SEC Filing  
5/9/2017Carole J ShapazianDirectorSell3,760$55.89$210,146.4016,226View SEC Filing  
5/8/2017Brik V EyreSVPSell130,732$55.69$7,280,465.0849,966View SEC Filing  
4/10/2017Albert P L StrouckenDirectorSell4,280$52.80$225,984.0025,667View SEC Filing  
3/29/2017James R Gavin IIIDirectorSell4,280$51.72$221,361.6034,980View SEC Filing  
2/22/2017Peter S HellmanDirectorSell4,280$49.81$213,186.8024,420View SEC Filing  
2/8/2017John D ForsythDirectorSell4,280$48.35$206,938.0031,338View SEC Filing  
5/23/2016Jose E AlmeidaCEOBuy11,691$42.75$499,790.2511,691View SEC Filing  
5/2/2016John D ForsythDirectorSell1,887$44.38$83,745.0626,320View SEC Filing  
4/4/2016John D ForsythDirectorSell1,887$41.75$78,782.2526,315View SEC Filing  
3/14/2016James R Gavin IIIDirectorSell5,660$40.34$228,324.4033,432View SEC Filing  
2/17/2016Peter S. HellmanDirectorSell5,660$38.35$217,061.0017,520View SEC Filing  
2/11/2016Kornelis J. StormDirectorSell5,660$35.98$203,646.8019,191View SEC Filing  
5/22/2015Carole J ShapazianDirectorSell1,533$67.68$103,753.44View SEC Filing  
4/27/2015James R Gavin IIIDirectorSell4,830$71.06$343,219.80View SEC Filing  
7/25/2014Carole J ShapazianDirectorSell1,645$76.98$126,632.10View SEC Filing  
7/24/2014Thomas T StallkampDirectorSell8,300$76.82$637,606.00View SEC Filing  
7/9/2014Ludwig HantsonVPSell24,693$76.00$1,876,668.00View SEC Filing  
5/2/2014Carole ShapazianDirectorSell5,680$75.28$427,590.405,146View SEC Filing  
4/23/2014Kees StormDirectorSell5,760$72.45$417,312.0015,156View SEC Filing  
4/21/2014Blake DevittDirectorSell4,334$73.12$316,902.0816,541View SEC Filing  
3/27/2014Sebastian BufalinoVPSell21,600$75.10$1,622,160.006,275View SEC Filing  
9/12/2013Carole ShapazianDirectorSell1,941$71.58$138,936.785,111View SEC Filing  
8/1/2013Robert L Parkinson JrCEOSell725,750$73.33$53,219,247.50View SEC Filing  
7/26/2013David P ScharfVPSell55,438$73.79$4,090,770.02View SEC Filing  
7/25/2013James R Gavin IIIDirectorSell5,760$72.82$419,443.20View SEC Filing  
7/24/2013Carole J ShapazianDirectorSell4,320$73.58$317,865.60View SEC Filing  
7/22/2013Robert J HombachCFOSell47,452$73.95$3,509,075.40View SEC Filing  
7/16/2013Phillip L BatchelorVPSell5,850$73.00$427,050.00View SEC Filing  
5/22/2013Blake E DevittDirectorSell1,000$72.34$72,340.00View SEC Filing  
5/20/2013Sebastian J BufalinoVPSell24,000$73.75$1,770,000.00View SEC Filing  
5/17/2013Robert M DavisVPSell130,800$73.00$9,548,400.00View SEC Filing  
9/13/2012Michael J BaughmanVPSell11,500$61.00$701,500.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Baxter International (NYSE BAX) News Headlines

Source:
DateHeadline
Baxter International Inc (BAX) Given Average Rating of "Buy" by BrokeragesBaxter International Inc (BAX) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - January 19 at 10:02 AM
Baxter to Present at the 7th Annual Leerink Partners Global Healthcare ConferenceBaxter to Present at the 7th Annual Leerink Partners Global Healthcare Conference
finance.yahoo.com - January 18 at 7:21 AM
Baxter (BAX) Launches Arisure Closed System Transfer Device - NasdaqBaxter (BAX) Launches Arisure Closed System Transfer Device - Nasdaq
www.nasdaq.com - January 16 at 7:09 AM
Baxter Launches Arisure Closed System Transfer Device to Help Prevent Hazardous Drug Exposure and Maintain ... - Business Wire (press release)Baxter Launches Arisure Closed System Transfer Device to Help Prevent Hazardous Drug Exposure and Maintain ... - Business Wire (press release)
www.businesswire.com - January 12 at 7:01 AM
Baxter Launches Arisure Closed System Transfer Device to Help Prevent Hazardous Drug Exposure and Maintain Medication SterilityBaxter Launches Arisure Closed System Transfer Device to Help Prevent Hazardous Drug Exposure and Maintain Medication Sterility
finance.yahoo.com - January 11 at 3:21 PM
Baxter to Host Fourth Quarter 2017 Financial Results Conference Call for InvestorsBaxter to Host Fourth Quarter 2017 Financial Results Conference Call for Investors
finance.yahoo.com - January 10 at 7:21 AM
$2.76 Billion in Sales Expected for Baxter International Inc (BAX) This Quarter$2.76 Billion in Sales Expected for Baxter International Inc (BAX) This Quarter
www.americanbankingnews.com - January 9 at 6:40 AM
Baxter Announces Agreement to Broaden Portfolio of Innovative Surgical ProductsBaxter Announces Agreement to Broaden Portfolio of Innovative Surgical Products
finance.yahoo.com - January 8 at 11:11 AM
[$$] Hospitals Wrestle With Shortage of IV Bags, Linked to Hurricane[$$] Hospitals Wrestle With Shortage of IV Bags, Linked to Hurricane
finance.yahoo.com - January 7 at 8:31 PM
Hospitals Lack IV Bags in Wake of Puerto Rico HurricaneHospitals Lack IV Bags in Wake of Puerto Rico Hurricane
www.msn.com - January 7 at 3:28 PM
[$$] Hospitals Lack IV Bags in Wake of Puerto Rico Hurricane[$$] Hospitals Lack IV Bags in Wake of Puerto Rico Hurricane
finance.yahoo.com - January 7 at 3:28 PM
$0.58 EPS Expected for Baxter International Inc (BAX) This Quarter$0.58 EPS Expected for Baxter International Inc (BAX) This Quarter
www.americanbankingnews.com - January 7 at 1:22 PM
Will Baxter International Inc (NYSE:BAX) Continue To Underperform Its Industry?Will Baxter International Inc (NYSE:BAX) Continue To Underperform Its Industry?
finance.yahoo.com - January 6 at 3:20 PM
Global Intravenous Solutions Market 2017-2022: Key Players are Ajinomoto, B. Braun Melsungen, Baxter International Inc., Grifols and Otsuka PharmaceuticalGlobal Intravenous Solutions Market 2017-2022: Key Players are Ajinomoto, B. Braun Melsungen, Baxter International Inc., Grifols and Otsuka Pharmaceutical
www.prnewswire.com - January 5 at 2:08 PM
Top Stock Reports for Wal-Mart, Citigroup & QualcommTop Stock Reports for Wal-Mart, Citigroup & Qualcomm
finance.yahoo.com - January 5 at 7:04 AM
Lombard Medical (EVARF) & Baxter International (BAX) Head-To-Head SurveyLombard Medical (EVARF) & Baxter International (BAX) Head-To-Head Survey
www.americanbankingnews.com - January 5 at 3:32 AM
Shareholder Value and Smart Acquisitions Are Priorities for This Health Care CEOShareholder Value and Smart Acquisitions Are Priorities for This Health Care CEO
finance.yahoo.com - January 4 at 3:21 PM
See How This Health Care CEO Puts Customer Value FirstSee How This Health Care CEO Puts Customer Value First
finance.yahoo.com - January 4 at 3:21 PM
Baxter International Inc (BAX) SVP Giuseppe Accogli Sells 28,641 SharesBaxter International Inc (BAX) SVP Giuseppe Accogli Sells 28,641 Shares
www.americanbankingnews.com - January 3 at 6:28 PM
Stocks Showing Improving Market Leadership: Baxter International Earns 83 RS RatingStocks Showing Improving Market Leadership: Baxter International Earns 83 RS Rating
finance.yahoo.com - January 3 at 11:13 AM
Baxter International (BAX) Stock Rating Upgraded by Raymond James FinancialBaxter International (BAX) Stock Rating Upgraded by Raymond James Financial
www.americanbankingnews.com - January 3 at 8:52 AM
Baxter International (BAX) Rating Lowered to Hold at Zacks Investment ResearchBaxter International (BAX) Rating Lowered to Hold at Zacks Investment Research
www.americanbankingnews.com - December 26 at 6:28 PM
Zimmer Biomet Suffers a Dull Knee Business & Supply Delay - NasdaqZimmer Biomet Suffers a Dull Knee Business & Supply Delay - Nasdaq
www.nasdaq.com - December 26 at 1:18 PM
Baxter International Inc (BAX) Given Average Recommendation of "Buy" by BrokeragesBaxter International Inc (BAX) Given Average Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - December 25 at 10:32 AM
Baxter International Inc (BAX) Expected to Post Quarterly Sales of $2.76 BillionBaxter International Inc (BAX) Expected to Post Quarterly Sales of $2.76 Billion
www.americanbankingnews.com - December 24 at 2:50 PM
5 Reasons Why You Should Buy Baxter (BAX) Stock Right Now - Nasdaq5 Reasons Why You Should Buy Baxter (BAX) Stock Right Now - Nasdaq
www.nasdaq.com - December 22 at 3:36 PM
$0.58 Earnings Per Share Expected for Baxter International Inc (BAX) This Quarter$0.58 Earnings Per Share Expected for Baxter International Inc (BAX) This Quarter
www.americanbankingnews.com - December 22 at 5:20 AM
ETFs with exposure to Baxter International, Inc. : December 21, 2017ETFs with exposure to Baxter International, Inc. : December 21, 2017
finance.yahoo.com - December 21 at 3:21 PM
Head-To-Head Survey: Asante Solutions (PUMP) vs. Baxter International (BAX)Head-To-Head Survey: Asante Solutions (PUMP) vs. Baxter International (BAX)
www.americanbankingnews.com - December 17 at 11:32 AM
Superb Measures for Quant Score Make Baxter International (BAX) a Strong Buy - Investorplace.comSuperb Measures for Quant Score Make Baxter International (BAX) a Strong Buy - Investorplace.com
investorplace.com - December 13 at 6:52 AM
Baxter to Present at the 36th Annual J.P. Morgan Healthcare ConferenceBaxter to Present at the 36th Annual J.P. Morgan Healthcare Conference
finance.yahoo.com - December 12 at 6:58 AM
Baxter International, Inc. – Value Analysis (NYSE:BAX) : December 11, 2017Baxter International, Inc. – Value Analysis (NYSE:BAX) : December 11, 2017
finance.yahoo.com - December 11 at 3:20 PM
Baxter International, Inc. breached its 50 day moving average in a Bearish Manner : BAX-US : December 7, 2017Baxter International, Inc. breached its 50 day moving average in a Bearish Manner : BAX-US : December 7, 2017
finance.yahoo.com - December 7 at 3:21 PM
ETFs with exposure to Baxter International, Inc. : December 7, 2017ETFs with exposure to Baxter International, Inc. : December 7, 2017
finance.yahoo.com - December 7 at 3:21 PM
Baxter International Inc. (BAX) SVP Jeanne K. Mason Sells 33,350 SharesBaxter International Inc. (BAX) SVP Jeanne K. Mason Sells 33,350 Shares
www.americanbankingnews.com - December 6 at 5:23 PM
Outstanding Analytics for Earnings Momentum Make Baxter International (BAX) a Strong Buy - Investorplace.comOutstanding Analytics for Earnings Momentum Make Baxter International (BAX) a Strong Buy - Investorplace.com
investorplace.com - December 6 at 7:30 AM
C.R. Bard (BCR) vs. Baxter International (BAX) Head-To-Head ContrastC.R. Bard (BCR) vs. Baxter International (BAX) Head-To-Head Contrast
www.americanbankingnews.com - December 5 at 9:30 PM
Outstanding Analytics for Earnings Momentum Make Baxter International (BAX) a Strong BuyOutstanding Analytics for Earnings Momentum Make Baxter International (BAX) a Strong Buy
investorplace.com - December 5 at 12:28 PM
Baxter to Present at the BMO Capital Markets Prescriptions for Success Healthcare ConferenceBaxter to Present at the BMO Capital Markets Prescriptions for Success Healthcare Conference
finance.yahoo.com - December 5 at 6:51 AM
Baxter International, Inc. : BAX-US: Dividend Analysis : December 01st, 2017 (record date) : By the numbers : December 4, 2017Baxter International, Inc. : BAX-US: Dividend Analysis : December 01st, 2017 (record date) : By the numbers : December 4, 2017
finance.yahoo.com - December 4 at 3:20 PM
Cover Story: Global Rush: Foreign life sciences companies flock to the TriangleCover Story: Global Rush: Foreign life sciences companies flock to the Triangle
www.bizjournals.com - December 1 at 3:21 PM
5 of the Most Efficient Stocks to Boost Your Portfolio5 of the Most Efficient Stocks to Boost Your Portfolio
finance.yahoo.com - December 1 at 3:21 PM
Heres Why You Should Invest in Baxter (BAX) Stock Right Now - NasdaqHere's Why You Should Invest in Baxter (BAX) Stock Right Now - Nasdaq
www.nasdaq.com - December 1 at 7:27 AM
Interpreting Baxter’s Recent Dividend AnnouncementInterpreting Baxter’s Recent Dividend Announcement
finance.yahoo.com - November 30 at 3:20 PM
Behind Baxter’s Recent Nexterone Injection RecallBehind Baxter’s Recent Nexterone Injection Recall
finance.yahoo.com - November 30 at 3:20 PM
Baxter International Inc. (BAX) Receives Average Recommendation of "Buy" from BrokeragesBaxter International Inc. (BAX) Receives Average Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - November 30 at 9:56 AM
Baxter International Inc. (BAX) Ex-Dividend Date Scheduled for November 30, 2017 - NasdaqBaxter International Inc. (BAX) Ex-Dividend Date Scheduled for November 30, 2017 - Nasdaq
www.nasdaq.com - November 30 at 7:01 AM
Understanding Baxter International’s Latest Wall Street RecommendationsUnderstanding Baxter International’s Latest Wall Street Recommendations
finance.yahoo.com - November 30 at 7:00 AM
Baxter International (BAX) a Strong Buy on High-Level Quant ScoreBaxter International (BAX) a Strong Buy on High-Level Quant Score
investorplace.com - November 28 at 11:52 AM
Baxter Canada Launches HDx Therapy Enabled by THERANOVA to Help Set New Standards of Care for Dialysis PatientsBaxter Canada Launches HDx Therapy Enabled by THERANOVA to Help Set New Standards of Care for Dialysis Patients
www.bizjournals.com - November 27 at 4:40 PM

SEC Filings

Baxter International (NYSE:BAX) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Baxter International (NYSE:BAX) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Baxter International (NYSE BAX) Stock Chart for Friday, January, 19, 2018

Loading chart…

This page was last updated on 1/19/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.